InvestorsHub Logo
Followers 0
Posts 13
Boards Moderated 0
Alias Born 05/12/2017

Re: None

Monday, 07/10/2017 9:29:42 AM

Monday, July 10, 2017 9:29:42 AM

Post# of 2808
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma.

Up to 40 patients are planned to be enrolled in this Phase 1b/2,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News